ReviewFrontiers in immunology2026
Metabolism of myeloid cells in brain tumors.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Primary and recurrent brain tumors are aggressive malignancies with high mortality rates and limited treatment options. Glioblastoma (GBM) in particular are largely refractory to immunotherapies despite harboring a significant proportion of immune cells in the tumor microenvironment (TME). Increasing evidence suggests that the immunosuppressive TME in brain tumors is driven by functional and metabolic reprogramming of resident and infiltrating myeloid cells. Here, we examine the determinants of immunometabolic landscape in brain tumors and distinct features of heterogeneous myeloid cell populations. We discuss how interactions between cell types and metabolic programs shape spatial niches. We further dissect the effect of tumor stage, type and therapy in informing metabolic features of the TME. Collectively, this systematic review provides an overview of myeloid cell metabolism in brain tumors and highlights potential opportunities for future studies targeting metabolic states for cancer immunotherapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.